Multiple myeloma
Conditions
Interventions
Patients will receive Lenalidomide(25mg on days 1-21) and dexamethazone(40mg on days1,8,15,22 in patinets aged between 20 to 74 and 20mg on days 1,8,15,22 in patinets aged 75 years or more) on 28-day
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Multiple myeloma diagnosed aged 20 years or more 2.Relapsed or refractory multiple myeloma without lenalidemide and medical history over the past 1 or 2 regimen 3.ECOG of Performance Status between 0 and 2 4.M protein in serum or urine is assessable. 5.Preserved function of major organs 6.Predicting survival time is more than 3 months. 7.Menopausal female or male and female who are enable to prevent conception by the adequate methods, including the surgical conception. 8.Informed consent in writing
Exclusion criteria
Exclusion criteria: 1.Previous treatment with lenalidomide 2.Hypersensitivity to lenalidomide and/or dexamethasone 3.non-secretory myeloma, solitary plasmacytoma, plasma cell leukemia, of POEMS syndrome 4.Positivity of HBs antigen or, HCV or HIV antibody 5.Uncontrollable liver dysfunction, renal dysfunction, cardiac dysfunction, respiratory dysfunction, diabetes mellitus, hypertension and infection 6.Double cancer requiring treatments 7.Psychoneurotic disorder, depression state or history 8.Patients with pregnancy, patients who may be pregnant, or patients during lactation 9.Pulomonary fibrosis, interstitial pneumonitis or interstitial shadow on chest CT, even if no symptom 10.Ineligible patient by physicians decision
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The serum cytokine level,chemokine level and the counts of peripheral lymphocytes. | — |
Countries
Japan
Contacts
Public ContactYasuyuki Nagata
Hamamatsu University School of Medicine Department of Internal Medicine III (Division of hematology)
Outcome results
None listed